Study S000951

Human Laboratory Screening of Semaglutide for Alcohol Use Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT05520775
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 48
Start: 2022-09-02
Primary completion: 2024-04-12
Lead sponsor: University of North Carolina, Chapel Hill
Conditions: Alcohol Use Disorder; Cigarette Smoking
Interventions: DRUG:Semaglutide; DRUG:Sham/placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: NIH:R21AA026931-02

Registered primary outcomes

Change in Alcohol Consumed [Baseline (Week 0) to post-medication (Week 8)]
Change in Breath Alcohol Concentration [Baseline (Week 0) to post-medication (Week 8)]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005391	Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. Hendershot CS, JAMA psychiatry	2025	Randomized trial	PMID 39937469 DOI	cites ClinicalTrials.gov:NCT05520775; registry reference DERIVED:39937469
R0047281	Once-Weekly Semaglutide in Adults With Alcohol Use Disorder Michael B. Paladino, Carolina Digital Repository (University of North Carolina at Chapel Hill)	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05520775